Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use. Objective: To provide consensus statements from the Biosimilar Working Group about the use of biosimilars in patients with psoriasis. Methods: A semi...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP
Format:	Artikel
Sprache:	English
Veröffentlicht:	Elsevier 2020-12-01
Schriftenreihe:	JAAD International
Schlagworte:	biosimilars interchangeability International Psoriasis Council psoriasis switching tumor necrosis factor inhibitors
Online Zugang:	http://www.sciencedirect.com/science/article/pii/S2666328720300523

Ähnliche Einträge

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
von: Zhou X, et al.
Veröffentlicht: (2021-07-01)

Biosimilars
von: Emel Bülbül Başkan
Veröffentlicht: (2022-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
von: Alexandra Azevedo, et al.
Veröffentlicht: (2018-09-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
von: Changkun Li, et al.
Veröffentlicht: (2023-12-01)

Portuguese Position Paper on the Use of Biosimilars in Psoriasis
von: Tiago Torres, et al.
Veröffentlicht: (2016-09-01)

Psoriasis vulgaris with fibrokeratoma from pityriasis amiantacea
von: Chihiro Shiiya, MD, et al.
Veröffentlicht: (2017-05-01)

Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in DenmarkCapsule Summary
von: Cæcilie Bachdal Johansen, MD, et al.
Veröffentlicht: (2022-06-01)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
von: Megna M, et al.
Veröffentlicht: (2022-07-01)

Psoriasis coxsackium
von: Daniel W. Cole, MD, et al.
Veröffentlicht: (2022-07-01)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
von: Rachel C. Ruda, et al.
Veröffentlicht: (2023-12-01)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
von: Rebecca Reese, et al.
Veröffentlicht: (2024-12-01)

Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvementCapsule Summary
von: Zarqa Ali, MD, PhD, et al.
Veröffentlicht: (2023-06-01)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
von: Tamara Gracia Cazaña, MD, PhD, et al.
Veröffentlicht: (2024-09-01)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
von: Kanako Tsunoda, MD, PhD, et al.
Veröffentlicht: (2024-09-01)

Ustekinumab Biosimilars
von: Elena Carmona-Rocha, et al.
Veröffentlicht: (2024-11-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
von: A. A. Soldatov, et al.
Veröffentlicht: (2019-03-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
von: Alan Menter
Veröffentlicht: (2023-10-01)

Late-onset development of psoriasis in Japan: a population-based cohort studyCapsule Summary
von: Haruka Goto, MD, et al.
Veröffentlicht: (2021-03-01)

On the Regulatory Approval Pathway of Biosimilar Products
von: Jun Wang, et al.
Veröffentlicht: (2012-03-01)

Sociodemographic factors have very little influence on adherence to topical drugs in patients with psoriasis
von: Mathias Tiedemann Svendsen, MD, PhD, et al.
Veröffentlicht: (2024-12-01)

Prognostic implications of high-sensitivity cardiac troponin in patients with suspected myocardial infarction with or without psoriasis
von: Sanaz A. Guldmann, MD, DPhil, et al.
Veröffentlicht: (2023-06-01)

Among psoriasis patients in Flanders, Belgium, a third has sexual dysfunction and almost half depression symptoms
von: Roel Van Overmeire, PhD, et al.
Veröffentlicht: (2025-02-01)

Facial psoriasis in a mask-like distribution
von: Cameron M.B. Zachary, MS, et al.
Veröffentlicht: (2021-01-01)

Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study
von: Yun Kyung Jang, MD, et al.
Veröffentlicht: (2023-03-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
von: Т. V. Korotaeva, et al.
Veröffentlicht: (2018-12-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
von: Mohammed Alqahtani, et al.
Veröffentlicht: (2024-11-01)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
von: Cohen SB, et al.
Veröffentlicht: (2023-10-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
von: Yuliya Lytvyn, PhD, et al.
Veröffentlicht: (2022-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
von: João Pedro Fernandes, et al.
Veröffentlicht: (2015-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
von: João Pedro Fernandes, et al.
Veröffentlicht: (2015-01-01)

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet
von: Jeffrey A. Bubley, MD, et al.
Veröffentlicht: (2021-11-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
von: Steven R. Feldman, et al.
Veröffentlicht: (2024-12-01)

Biosimilars, the journey has begun
von: Alba Martos-Rosa, et al.
Veröffentlicht: (2015-01-01)

A pustular psoriasis flare treated with calcium supplementation
von: Laure Masson, MD, et al.
Veröffentlicht: (2021-06-01)

Nanotomography of lesional skin using electron microscopy reveals cytosolic release of nuclear DNA in psoriasis
von: Eric Lindberg, PhD, et al.
Veröffentlicht: (2021-03-01)

The Problem of Anti-Cytokine Therapy in Psoriasis Patients
von: Ramina K. Keshileva, PhD
Veröffentlicht: (2012-09-01)

Cardiovascular Complications During Delivery Hospitalization in Patients With Psoriasis
von: Ankit Agrawal, MD, et al.
Veröffentlicht: (2025-02-01)

Onset of rupioid psoriasis after vasodilatory regimen initiation in a patient with pulmonary arterial hypertension
von: Uros Rakita, MSc, et al.
Veröffentlicht: (2021-06-01)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
von: Ronald Vender, MD, et al.
Veröffentlicht: (2022-09-01)

Societal impact for patients with psoriasis: A nationwide Swedish register studyCapsule Summary
von: Henrike Häbel, PhD, et al.
Veröffentlicht: (2021-06-01)